In 2010, the centre for the AIDS Programme of Research in South Africa (CAPRISA)004 and iPrEx trials (microbicide gel containing tenofovir and oral pill containing tenofovir-emtricitabine, respectively) demonstrated that antiretroviral preexposure prophylaxis (PrEP) reduced the risk of HIV acquisition among high-risk individuals. To determine the facilitators and barriers to PrEP provision by health-care providers, we conducted an online, quantitative survey of Massachusetts-area physicians following the publication of the CAPRISA and iPrEx results. We assessed awareness and comprehension of efficacy data, prescribing experience, and anticipated provision of oral and topical PrEP among physicians, as well as demographic and behavioral factors associated with PrEP awareness and prescribing intentions. The majority of HIV specialists and generalist physicians were aware of data from these PrEP trials and able to correctly interpret the results, however, correct interpretation of findings tended to vary according to specialty (i.e., HIV specialists had greater awareness than generalists). In addition, provider concerns regarding PrEP efficacy and safety, as well its ability to divert funds from other HIV prevention resources, were associated with decreased intentions to prescribe both oral and topical PrEP. Findings suggest that a substantial proportion of physicians who may have contact with at-risk individuals may benefit from interventions that provide accurate data on the risks and benefits of PrEP in order to facilitate effective PrEP discussions with their patients. Future studies to develop and test interventions aimed at health-care providers should be prioritized to optimize implementation of PrEP in clinical settings.
Introduction
Despite the widespread use of behavioral interventions to prevent HIV, more than two million new infections occur worldwide annually, including about 50,000 in the USA (Hall et al., 2008) . In July 2010, the centre for the AIDS Programme of Research in South Africa (CAPRISA)004 trial was the first to demonstrate the efficacy of topical preexposure chemoprophylaxis (PrEP) in South African women through the pericoital use of an intravaginal microbicide gel containing tenofovir to reduce HIV acquisition (Abdool Karim et al., 2010) . In November 2010, the iPrEx study established that a once-daily tablet containing a fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) successfully reduced the risk of HIV acquisition among at-risk men who have sex with men (MSM) and transgender women (Grant et al., 2010) . These findings warrant the need for at-risk individuals to access health-care providers who are knowledgeable about HIV transmission and prevention modalities and trained and motivated to prescribe chemoprophylaxis.
Since the release of PrEP efficacy data, few studies have measured health-care providers' awareness of PrEP and ability to correctly interpret clinical efficacy data (Maznavi, Hardy, & Bredeek, 2011; White, Mimiaga, Krakower, & Mayer, 2012) . Given prior research documenting potential barriers to PrEP provision, including historic antiretroviral use for HIV treatment, diversion of limited resources, and concern for unintended consequences (e.g., medication toxicities, behavioral disinhibition, and the emergence of drug resistance) (Arnold et al., 2012; Paltiel et al., 2009; Supervie, García-Lerma, Heneine, & Blower, 2010; Tripathi, Ogbuanu, Monger, Gibson, & Duffus, 2012; Underhill, Operario, Skeer, Mimiaga, & Mayer, 2010) , it is essential to understand provider knowledge, attitudes, and prescribing intentions regarding PrEP. Guided by the theory of reasoned action/planned behavior (Ajzen & Madden, 1986; Boldero, Sanitioso, & Brain, 1999) , we assessed Massachusetts-area physicians' awareness and comprehension of efficacy data, prescribing experience, and anticipated provision of PrEP using an online, quantitative survey. To inform the content of future educational interventions for physicians, specific concerns and hypothetical motivators around PrEP provision were also assessed.
Methods
Details of this study have been described previously (White et al., 2012) . Briefly, Massachusetts HIV specialists and generalist physicians were recruited to complete an anonymous, online survey assessing their attitudes, knowledge, and experiences with biomedical and other HIV prevention interventions. The survey was completed by 115 physicians (response rate 18.4%) and approved by the Institutional Review Board of Fenway Health.
The survey contained four domains designed to assess providers' knowledge, experiences, and beliefs regarding PrEP after the release of iPrEx clinical trial data (see Table 1 ): (1) demographics and provider characteristics; (2) PrEP-related knowledge, experience, and preferences; (3) perceived motivators and barriers to PrEP provision; and (4) awareness and interpretation of PrEP efficacy data.
To assess the differences between provider specialty and the measures described above, t-tests (for continuous measures), chi-squared tests (for nominal measures), and Fisher's exact tests (for nominal measures with low cell counts) were performed. Bivariate regression analyses were conducted to examine the factors associated with knowledge and intentions to prescribe PrEP. A principal components analysis of the 15 items assessing PrEPrelated concerns was conducted to enable these factors to be orthogonal in the multivariable regression models. Using Kaiser's "rule of one," a scree plot of eigenvalues (Jolliffe, 2002) determined the number of principal components to retain in our analysis, yielding 5. The five principal components explained 71% of the total variance of the items and items with a loading of 0.40 absolute value or higher were used to construct corresponding names (DeVellis, 2003) (see Table 2 ).
Results
Demographic characteristics (n = 115) by specialty type are shown in Table 3 . Awareness of iPrEx and CAPRISA efficacy data was moderate (64% and 57%, respectively) (Table 4) . Overall, 72% correctly interpreted the results of both trials, and 60% specified the correct dosing of the pill (everyday) and gel (before/after every act of vaginal sex). A greater proportion agreed that the gel (70%) versus the pill (40%) should be available to all at-risk persons. Notably, 28% of physicians felt that the pill should not be available to all at-risk persons. The majority indicated that they would prescribe the pill (76%) and gel (83%) to the populations in which efficacy had been demonstrated. However, a majority also said that they would prescribe the pill (52%) and gel (53%) to uninfected individuals in serodiscordant relationships or to individuals engaged in transactional sex (56%), despite the absence of efficacy trials restricted to these populations.
HIV specialists were more knowledgeable than generalists about the results of iPrEx (p < 0.001) and CAPRISA (p < 0.001) and, more often than generalists, indicated that the pill should be prescribed to people who change partners frequently (p < 0.05) ( Table 4 ).
In the first multivariable model, factors resulting in lower odds of intending to prescribe oral PrEP included: data demonstrating greater than 80% efficacy, beliefs that behavioral interventions are safer/more effective, concerns regarding PrEP's efficacy/safety, and concerns regarding decreases in federal funds for other HIV prevention modalities (p ≤ 0.05). Conversely, additional clinical efficacy data about MSM were associated with the increased odds of intending to prescribe oral PrEP (p = 0.05) ( Table 5 ).
In the second multivariable model, factors resulting in lower odds of intending to prescribe topical microbicides included: beliefs that behavioral interventions are safer/more effective and concerns regarding decreases in federal funds for other HIV prevention modalities (p ≤ 0.01) ( Table 5) .
Discussion
In 2010, CAPRISA004 (Abdool Karim et al., 2010) and iPrEx (Grant et al., 2010) provided the first proof of antiretroviral chemoprophylaxis for HIV infection. In this study of PrEP awareness and prescribing intentions among 115 Massachusetts physicians, we found that a majority of HIV specialists and generalists were aware of CAPRISA004 and iPrEx data and were able to correctly interpret the results of these studies. However, the finding that participants misinterpreted the results of oral and topical PrEP efficacy data raises concerns about how to best educate physicians to translate the results of PrEP efficacy studies. These concerns suggest that educational interventions designed to increase physicians' awareness and interpretation of PrEP study data may be needed to optimize PrEP provision, given the recent US Food and Drug Administration (FDA) approval of oral PrEP for MSM and at-risk heterosexuals (Centers for Disease Control and Prevention [CDC], 2012a [CDC], , 2012b .
We found that generalists were less familiar with PrEP efficacy results than were HIV specialists, which is particularly relevant since most persons at risk for HIV are not likely to seek care from HIV specialists. Given that physicians are not often comfortable discussing sexual behavior with their patients (Bernstein et al., 2008; Epstein et al., 1998; Petroll & Mosack, 2011) , innovative provider education programs are needed for PrEP to be effective in decreasing HIV spread. Moderate provider willingness to prescribe oral/topical PrEP to 
Efficacy data interpretation
This study showed that the TDF/FTC pill reduced HIV infections by 44% among HIV-uninfected MSM who were assigned to take the active medication daily. How do you interpret these results?
(1) A man taking the pill, who had sex 100 times without a condom, would be protected the first 44 times; (2) A man would be protected from HIV 44% of the time if he takes the pill daily; (3) One pill a day protects against HIV 44% of the time, two pills a day protect against HIV 88% of the time; (4) The pill may be expected to prevent 44% of the infections that would occur in a population if the pill wasn't used; (5) If a man had sex while using the pill, his chances of getting HIV will be 44% less than if he hadn't been taking the pill at all; (6) Other; (7) I am not sure how to interpret the results
Dosing interpretation
Based on the results of this study, how regularly do you think HIV-uninfected people will need to take the TDF/FTC pill for it to be protective against HIV transmission?
(1) Every day; (2) Within one day of sexual exposure and within one day after exposure; (3) Within one day of sexual exposure and as soon as possible after exposure; (4) At least once a week; (5) At least twice a week; (6) At least three times a week; (6) At least four times a week; (7) At least five times a week; (8) At least six times a week TDF/FTC pill should be readily available to all at-risk persons
Based on the results of this study, do you believe that the TDF/ FTC pill should be readily available to all persons at-risk for HIV infection?
(1) Strongly agree; (2) Agree; (3) Neutral; (4) Disagree; (5) Strongly disagree
Provision of TDF/FTC pill by population type Based on these study results, for which, if any, of these groups, would you prescribe the TDF/FTC pill to prevent against HIV infection? Note: unless otherwise specified, assume groups to be based in the USA
(1) Study population (i.e., high-risk men who have sex with men); (2) Injection drug users; (3) People with a sexually transmitted disease; (4) People who change sex partners frequently; (5) People who exchange sex for money, drugs or other goods;
populations for which efficacy data exist suggests that physicians may not always base their prescribing decisions solely on available evidence. Thus, further studies are needed to understand how physicians formulate their prescribing decisions. In addition, given the links between physicians' concerns about PrEP (behavioral interventions are safer and PrEP would divert HIV prevention resources) and their prescribing intentions, educational interventions that provide information on the safety of PrEP and its anticipated financial impact on HIV prevention budgets, may be most effective in motivating physicians to appropriately prescribe PrEP.
The findings that many HIV specialists were aware of PrEP and that physicians may be willing to prescribe PrEP to populations with and without efficacy data are consistent with the findings from another post-iPrEx study of HIV specialists in the USA (Maznavi et al., 2011) . Moreover, our results that safety and efficacy concerns may be important barriers to prescribing PrEP are also consistent with findings from Maznavi and colleagues as well as another study of health-care providers before the release of PrEP efficacy data (Tripathi et al., 2012) . Our study extends the current understanding of physicians' knowledge of PrEP by A recent study found that topical coital gel containing the HIV antiretroviral drug tenofovir was effective in reducing HIV infections among HIV-uninfected women in Africa. Among the women who were assigned to use the tenofovir gel within 12 hours before and after sex, there were 39% fewer infections compared to women who were assigned to use the placebo gel. Before this survey, had you previously heard these results?
(1) Yes; (2) No
Efficacy data interpretation Among the women who were assigned to use the tenofovir gel within 12 hours before and after sex, there were 39% fewer infections compared to women who were assigned to use the placebo gel. How do you interpret these results?
(1) If a woman using the gel had sex 100 times without a condom, she would be protected the first 39 times; (2) A woman would be protected from HIV 39% of the time if she uses the gel before and after sex; (3) One dose of the gel protects against HIV 39% of the time -two doses protect against HIV 78% of the time; (4) The gel may be expected to prevent 39% of the infections that would occur in a population if the gel wasn't used; (5) If a woman has sex while using the gel, her chances of getting HIV will be 39% less than if she had not been using the gel; (6) Other; (7) I am not sure how to interpret the results
How regularly do you think HIV-uninfected people will need to use a vaginal gel for it to be protective against HIV transmission?
(1) Every day; (2) Before and after every act of vaginal sex; (3) Before every act of vaginal sex and as soon as possible after exposure; (4) At least once a week; (5) At least twice a week; (6) At least three times a week; (7) At least four times a week; (8) At least five times a week; (9) At least six times a week Tenofovir gel should be readily available to all at-risk persons
Based on the results of this study, do you believe that the tenofovir gel should be readily available to all persons at-risk for HIV infection?
Provision of tenofovir gel by population type
Based on these study results, for which, if any, of these groups, would you prescribe the tenofovir gel to prevent against HIV infection? Note: unless otherwise specified, assume groups to be based in the USA Other workplace = Physician practice group, Independent practice group, AIDS service organization, Health department, Academic or Corporation. *p < 0.05; **p < 0.01; ***p < 0.001. " + " Fisher's exact test was used due to low cell count. demonstrating that physicians may misinterpret the results of PrEP efficacy studies. As accurate communication of the potential risks and benefits of PrEP from physicians to their patients will be essential for patients to make informed decisions about PrEP utilization, our results suggest that future studies measuring physician and patient understanding of PrEP clinical efficacy data are warranted. These results should be interpreted in the context of the cross-sectional study design. Study participants represent a subset of physicians, so findings may not be generalizable to all physicians in Massachusetts, or elsewhere. As the study was conducted soon after iPrEx publication, the results could underestimate physicians' current awareness of PrEP (AIDS Healthcare Foundation, 2012; Associated Press, 2012; Baeten & Celum, 2012; Mutua et al., 2012; Susman, 2012; Tuller, 2011) . However, the perceived motivators and barriers analyzed are similar to those described by providers in a qualitative study of clinicians' perceived challenges to implementing PrEP (Arnold et al., 2012) , suggesting it is unlikely that we excluded important factors that would alter our overall conclusions.
This study suggests that a substantial proportion of physicians who may have contact with at-risk individuals may benefit from interventions that provide accurate data on the risks and benefits of PrEP in order to provide effective counseling regarding PrEP utilization. Future studies to develop and test interventions targeted at health-care providers should be prioritized to optimize implementation of PrEP in clinical settings.
